The price-to-earnings ratio for Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is above average at 17.69x. The 36-month beta value for JAZZ is also noteworthy at 0.57. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 9 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAZZ is 57.91M, and at present, short sellers hold a 7.34% of that float. The average trading volume of JAZZ on December 20, 2024 was 626.04K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
JAZZ) stock’s latest price update
The stock price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has surged by 0.91 when compared to previous closing price of 121.74, but the company has seen a -0.61% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-17 that DUBLIN, Dec. 17, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
JAZZ’s Market Performance
Jazz Pharmaceuticals plc (JAZZ) has experienced a -0.61% fall in stock performance for the past week, with a 5.16% rise in the past month, and a 10.92% rise in the past quarter. The volatility ratio for the week is 3.00%, and the volatility levels for the past 30 days are at 2.67% for JAZZ. The simple moving average for the past 20 days is 0.04% for JAZZ’s stock, with a 9.02% simple moving average for the past 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Morgan Stanley repeating the rating for JAZZ by listing it as a “Overweight.” The predicted price for JAZZ in the upcoming period, according to Morgan Stanley is $175 based on the research report published on December 12, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $169. The rating they have provided for JAZZ stocks is “Buy” according to the report published on June 05th, 2024.
Robert W. Baird gave a rating of “Outperform” to JAZZ, setting the target price at $160 in the report published on January 03rd of the current year.
JAZZ Trading at 3.84% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.44% of loss for the given period.
Volatility was left at 2.67%, however, over the last 30 days, the volatility rate increased by 3.00%, as shares surge +3.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.47% upper at present.
During the last 5 trading sessions, JAZZ fell by -0.61%, which changed the moving average for the period of 200-days by +4.83% in comparison to the 20-day moving average, which settled at $122.81. In addition, Jazz Pharmaceuticals plc saw -0.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from COZADD BRUCE C, who sale 2,000 shares at the price of $121.17 back on Dec 02 ’24. After this action, COZADD BRUCE C now owns 427,025 shares of Jazz Pharmaceuticals plc, valued at $242,340 using the latest closing price.
Carr Patricia, the SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sale 53 shares at $122.49 during a trade that took place back on Dec 02 ’24, which means that Carr Patricia is holding 6,596 shares at $6,492 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.78 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 12.09, with 3.95 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.47. The interest coverage ratio of the stock is 2.67.
Currently, EBITDA for the company is 1.29 billion with net debt to EBITDA at 2.74. When we switch over and look at the enterprise to sales, we see a ratio of 2.85. The receivables turnover for the company is 5.52for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.26.
Conclusion
In summary, Jazz Pharmaceuticals plc (JAZZ) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
